Please select


For My Business

< R10m annual turnover

For My Business

> R10m annual turnover

Please select


For My Business

< R10m annual turnover

For My Business

> R10m annual turnover

Switch to FNB Business

Product shop

By Turnover

First Business Zero (R0 - R5 million p.a) Gold Business (R0 - R5 million p.a) Platinum Business (R5 million - R60 million p.a) Enterprise Business (R60 million - R150 million+ p.a)

Transact

Business Accounts Credit Cards Cash Solutions Merchant Services eWallet Pro Staffing Solutions ATM Solutions Ways to bank Fleet Services Guarantees

Savings and Investments

Save and Invest 3PIM (3rd Party Investment Manager)

Borrow

FNB Cash Advance Overdraft Loans Debtor Finance Leveraged Finance Private Equity Securities Based Lending Selective Invoice Discounting Asset Based Finance Alternative Energy Solutions Commercial Property Finance Fleet Services

Insure

Insurance

For my employees

Staffing Solutions Employee benefits

Forex + Trade

Foreign Exchange Imports and exports Structured Trade + Commodity Finance Business Global Account (CFC account)

Value Adds + Rewards

Connect my business the dti initiatives Enterprise and supplier development Business Hub eBucks Rewards for Business DocTrail™ CIPC Integration Channel Instant Accounting Solutions Instant Payroll Instant Cashflow Instant Invoicing SLOW 24/7 Business Desk FNB Business Fundaba nav» Marketplace Prepaid products Accounting integrations

Industry Expertise

Philanthropy Chinese Business Islamic Banking Agriculture Public Sector Education Healthcare Franchise Motor Dealership Tourism

Going Global

Global Commercial Banking

Financial Planning

Overview

Bank Better

KYC / FICA Debit order + recipient switching Electronic Alerts

Corporates + Public Sector

Corporate Public Sector

All savings + investment accounts


Cash deposits

Notice deposits Immediate access Access to a portion Fixed deposits

Share investing

Shares

Tax-free investing

Tax-free accounts

Funds/unit trusts

Ashburton specialised products

Invest abroad

Offshore products

I want to save for

Personal goals Child's education Emergencies Tax-free

Compare similar

Compare

Additional options

Show me all Help me chosse Find an advisor

Financial planning

Overview

Back

Trade Ideas

Global trade idea - IDEX Corporation (IEX US) - BUY

 

IDEX is a leading engineer of fluidics and optics systems, fire and rescue equipment, as well as other specialty products. The company operates in the niche applied-solutions market, developing industrial-use pumping and dispensing equipment, lubrication systems, banding and clamping devices, as well as rescue tools. IDEX serves various customers worldwide.

Fundamentally, the company has remained highly acquisitive- strengthening and expanding its businesses through strategic asset additions. Growth has been underpinned by the group's solid product portfolio, successful execution abilities, and investments into increasing geographic exposure, particularly to emerging markets, as well as productivity enhancement and digitisation. The company displayed robust growth during 1Q23, with earnings and revenue increasing ~7% and ~12% respectively, as demand (particularly in the industrial and chemical end-markets) stood firm. This represented a strong start to the new year, with the company already well-poised to build on an impressive FY22.

Technically, the stock is trading above its key support level (see the black trendline on the first chart), which acts as a barrier to prevent any downwards movement of the price. This support level, underpinned by strong demand, is indicative of a potential price reversal to the upside, thus making the stock an attractive investment opportunity.

The stock is currently trading below its 200-day simple moving average (SMA) of ~$218. We take a counter-trend strategy in anticipation of a price correction in the near term.

Our bullish view is supported by the emergence of upside momentum as per the MACD indicator. The Coppock Curve (which recently formed a trough), as well as the On-Balance Volume indicator (which is trending sidewards) further substantiate our stance.

 

 

Share Information

Share code IEX US
Industry Industrial Equipment
Market Capital (USD) 16.07 billion
One year total return 18.60%
Return year-to-date -6.07%
Current price (USD) 212.62
52 Week high (USD) 246.23
52 Week low (USD) 177.26
Financial year end December
Closing paragraph The share price has come under some pressure recently, though various technical indicators point toward an imminent correction.

Consensus Expectations (Bloomberg)

FY22 FY23E FY24E FY25E
Headline Earnings per Share (USD) 8.12 8.68 9.09 9.31
Growth (%) 6.87 4.78 2.37
Dividend Per Share (USD) 2.40 2.54 2.71 2.80
Growth (%) 5.94 6.62 3.33
Forward PE (times) 24.50 23.38 22.84
Forward Dividend Yield (%) 1.16 1.23 1.32
Closing paragraph Earnings growth is expected to remain strong over FY23, which given the group's strong free cash flow generation should allow sufficient room for IDEX to carry out its objective of returning value to shareholders.

Buy/Sell Rationale

Technical Analysis:

  • On the second chart we see a bullish crossover of the MACD indicator. This signals an upward reversal of the price trend, providing further support to our stance.
  • Our entry range is between $210 and $220 - a drop below this level would indicate a structural change in the trend, providing reason to negate the trade idea.
  • Our target price is $240, which represents a gain of ~13% from current levels.
  • Forward calculations of the RSI suggest that the stock will be in overbought territory at around $290, making our profit target realistic.
  • The current RSI reading of 50, compared to readings of 30 for oversold territory and 70 for overbought territory, leaves sufficient room for further upside.
  • The proposed time to exit is mid-October 2023, though investors can adjust for either a longer or shorter time horizon, depending on price behaviour.
  • A drop below $200 (~6% downside from current levels) will be a major concern, and as such is recommended as a stop-loss.
  • We suggest a medium capital at-risk allocation for this trade. Increase exposure for a break above $218.

Long-term fundamental view:

  • IDEX operates across three business segments: Health & Science Technologies (HST), which generates more than 40% of its total revenue, Fluid & Metering Technologies (FMT), which brings in around 35%, as well as Fire & Safety/Diversified Products (FSDP), which contributes in excess of 20%. Through these segments, the company provides various solutions to customers within the agriculture, food & beverage, industrial infrastructure, fire & safety, and pharmaceutical industries.
  • The company is headquartered in the US (where ~50% of its revenue is generated) but also has manufacturing operations across ~20 other countries. The diverse product portfolio is underpinned by the ownership of over 50 different subsidiaries (including Alfa Valvole, Precision Polymer Engineering and Jaws of Life).
  • Growth over FY22 was strong, with organic revenue increasing 13% y/y, due to robust demand across the various channels. The top-line was also boosted by a number of strategic business acquisitions which contributed an additional 2% to growth. A meticulous pricing strategy, coupled with disciplined cost controls, led to further margin expansion and this ultimately drove an impressive earnings performance (+29% y/y).
  • Increasing market share has enabled IDEX to outperform its industry peers (from an operational point of view) over the past year. Much of this is attributable to its diverse nature, which has seen weakness in some industries being offset by strong gains in others.
  • A high level of order backlogs should support growth over the medium-term, and divestitures of various non-aligned businesses supportive of focused growth.
  • IDEX faces a few potential risks going forward, including supply-chain pressures (OEM shipment delays), input-cost inflation and currency-conversion volatility impacting offshore revenue. The Health & Science Technology business, in particular, is exposed to weakness within the pharmaceuticals, biopharma and nutrition end-markets.

Share Name and position LIT - Take Profit
(Close the Position)
BLK - Buy
(Continue to hold)
AIG - Buy
(Continue to hold)
Entry 62.48 684.91 54.72
Current 68.84 739.80 58.89
Movement 10.2% 8.0% 7.6%
Summary text We closed the trade early to lock in profit and reduce portfolio risk. We remain interested in the rising wedge pattern as displayed by the stock price. Trading continues above the 200-day simple moving average and upward momentum is supportive.

Our profit target is $765 with a trailing stop-loss at $705. Exit the position around 23 August 2023.
The stock is trading in a falling wedge pattern within a previous uptrend. The stock is slightly above its 200-day simple moving average. Upward momentum supports the bullish bias.

Our profit target is $71 with a trailing stop-loss at $63.50. Exit the position on 30 August 2023.

Share Name and position HACK - BUY
(Continue to hold)
FCX - Buy
(Continue to hold)
FOXF - Buy
(Continue to hold)
Entry 47.58 39.71 105.69
Current 51.01 42.08 111.00
Movement 7.2% 6.0% 5%
Summary text The price remains above critical support levels and trade continues above the 200-day simple moving average. Momentum has shifted back to the upside.

Our profit target is $55 with a trailing stop-loss of $49. Exit the position around 4 August 2023.
Price action reflecting some symmetry is of interest. The stock is trading above its 200-day simple moving average. Emerging upside momentum provides further support.

Our profit target is $47 with a trailing stop-loss at $38.90. Exit the position around 18 October 2023.
Price action depicting higher highs and higher lows remains attractive. The stock is testing is 200-day simple moving average. Emerging upside momentum provides further support.

Our profit target is $126 with a trailing stop-loss of $103. Exit the position around 6 October 2023.

How would you like to log in?